fda warning letter compounded semaglutide september 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA Issues 30 Warning Letters

Pregnancy and breastfeeding: Retatrutide is unlicensed and its safety in pregnancy or during breastfeeding has not been established

2010;34:S47S55

Despite active lifestyles and access to fitness resources, many adults continue to struggle with obesity, excess weight, insulin resistance, metabolic health concerns, and long-term weight management

For a deeper look at how semaglutide compounding works overall, the complete guide to compounded semaglutide covers the fundamentals

In this guide, well walk you through the key differences and similarities between these two medicationshow they work, how much weight you can expect to lose, what they cost, whether insurance might cover them, and more